E

Importance and Prospect of Maintenance Treatment in Post-SCT MM Patients

By Ehsan Malek
February 28, 2022
1 Comment
Login to view comments. Click here to Login

Related Content

AUTOPLAY
23:18
Oncology Data Advisor

Can Diet and Nutrition Impact Multiple Myeloma Outcomes?

Feat. U. Shah, R. Banerjee
10:50
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Updates on the Efficacy and Safety of Cilta-Cel in R/R MM: …

Feat. A. Jakubowiak
33:28
Cleveland Clinic Taussig Cancer Institute

Management of Relapsed/Refractory Multiple Myeloma

Feat. F. Anwer
17:59
Parameswaran Hari

Delivering the Best Initial Treatment for Myeloma: Induction Therapy…

26:18
Morie Gertz

Treatment of Relapsed Myeloma: Overview of Approved Drugs & Opti…

04:41
Joshua Richter

Examining Triplet Therapy in MM: Analysis of ELOQUENT-3 and MAIA Tri…

15:12
Yale Cancer Center

ASH 2021: Cellular Therapies in Myeloma

Feat. N. Bar
26:02
Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

2022 Novel Immune-Based Therapy for R/R MM: Interactive Case Discuss…

Feat. J. Brayer
25:51
KU ASH 2018 Review: Current Updates in Hematologic Diseases

MM - Overview of Trials Presented at ASH 2018

Feat. A. Abdallah
08:15
2018 Pan Pacific Lymphoma Conference

Evolution of Myeloma Induction Regimens

Feat. S. Holstein
14:15
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

MRD in Multiple Myeloma Isn't Ready for Prime Time: More Patient…

Feat. T. Martin
05:09
Association of Community Cancer Centers (ACCC)

72 y/o Woman With IgG Lambda High-Risk Multiple Myeloma (del17p): Di…

Feat. K. Maples
08:34
Pashna Munshi

Is ASCT Safe and Effective for Multiple Myeloma Patients Aged 70 or Older?

31:09
Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

2022 Updates on BCMA CAR T-Cell for MM: Real World Experience and Future P…

Feat. M. Alsina
15:11
Ajay Nooka

Early Relapse: Choosing Among Different Second Line Regimens in Myel…

13:12
ASH 2021 Conference Coverage on VuMedi

ASH 2021: Addressing Current Questions and Controversies in the Mana…

Feat. M. Gertz
10:47
SOHO Highlights: State of the Art and Next Questions

Surveying the Induction and Maintenance Therapy Landscape in Newly D…

Feat. S. Lonial
06:31
2nd SOHO Italian Conference

Treatment Options for the R/R MM Patients: A Review of the Current D…

Feat. K. Anderson
18:43
7th Eurasian Hematology Oncology Summit

2020 Updates on CAR-T in R/R MM: What Is the Incidence of AEs With bb2121?…

Feat. E. Terpos
31:49
Moffitt Cancer Center

AL Amyloidosis at Moffitt: How Does SCT Affect OS? Is Bortezomib/Ixazomib …

Feat. B. Blue